BACKGROUND: Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor, which has been associated with total and cardiovascular mortality in various clinical settings. Studies on its structural isomer, symmetric dimethylarginine (SDMA), are scarce. This study aimed to determine the associations of both ADMA and SDMA levels with secondary cardiovascular disease events and all-cause mortality in patients with stable coronary heart disease (CHD). METHODS: In the observational prospective cohort study KAROLA, 1,148 CHD patients were followed for a median of 8.1 years. ADMA and SDMA were determined by liquid chromatography-tandem mass spectrometry. Baseline ADMA and SDMA levels were categorized in quartiles or standardized by their respective standard deviation, and appropriate hazard ratios and 95 % confidence intervals (HR [95 % CI]) were estimated in Cox proportional hazards models. RESULTS: 150 patients experienced secondary cardiovascular disease events (CVD) and 121 patients died. After adjustment for confounders, ADMA was not associated with the risk of secondary CVD events (HR per standard deviation increase: 1.02 [95 %CI: 0.86-1.21]), whereas an association was suggested for SDMA (HR 1.17 [1.00-1.37]). Higher hazard ratios were observed in all-cause mortality models (ADMA: HR 1.15 [0.95-1.37]; SDMA: HR 1.29 [1.09-1.52]). CONCLUSIONS: Our results suggest that especially SDMA might possibly have potential as a risk marker for all-cause mortality and to a lesser extent for secondary cardiovascular events. Future studies are needed to quantify these associations more precisely and should, in particular, further address the possibility of residual confounding by impaired kidney function.
BACKGROUND: Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor, which has been associated with total and cardiovascular mortality in various clinical settings. Studies on its structural isomer, symmetric dimethylarginine (SDMA), are scarce. This study aimed to determine the associations of both ADMA and SDMA levels with secondary cardiovascular disease events and all-cause mortality in patients with stable coronary heart disease (CHD). METHODS: In the observational prospective cohort study KAROLA, 1,148 CHD patients were followed for a median of 8.1 years. ADMA and SDMA were determined by liquid chromatography-tandem mass spectrometry. Baseline ADMA and SDMA levels were categorized in quartiles or standardized by their respective standard deviation, and appropriate hazard ratios and 95 % confidence intervals (HR [95 % CI]) were estimated in Cox proportional hazards models. RESULTS: 150 patients experienced secondary cardiovascular disease events (CVD) and 121 patients died. After adjustment for confounders, ADMA was not associated with the risk of secondary CVD events (HR per standard deviation increase: 1.02 [95 %CI: 0.86-1.21]), whereas an association was suggested for SDMA (HR 1.17 [1.00-1.37]). Higher hazard ratios were observed in all-cause mortality models (ADMA: HR 1.15 [0.95-1.37]; SDMA: HR 1.29 [1.09-1.52]). CONCLUSIONS: Our results suggest that especially SDMA might possibly have potential as a risk marker for all-cause mortality and to a lesser extent for secondary cardiovascular events. Future studies are needed to quantify these associations more precisely and should, in particular, further address the possibility of residual confounding by impaired kidney function.
Authors: Friedrich Schulze; Henrike Lenzen; Christoph Hanefeld; Asja Bartling; Karl J Osterziel; Lilia Goudeva; Caroline Schmidt-Lucke; Magda Kusus; Renke Maas; Edzard Schwedhelm; Dietrich Strödter; Bernd C Simon; Andreas Mügge; Werner G Daniel; Harald Tillmanns; Bernhard Maisch; Thomas Streichert; Rainer H Böger Journal: Am Heart J Date: 2006-09 Impact factor: 4.749
Authors: Donald Lloyd-Jones; Robert J Adams; Todd M Brown; Mercedes Carnethon; Shifan Dai; Giovanni De Simone; T Bruce Ferguson; Earl Ford; Karen Furie; Cathleen Gillespie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; P Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary M McDermott; James Meigs; Dariush Mozaffarian; Michael Mussolino; Graham Nichol; Véronique L Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan D Wong; Judith Wylie-Rosett Journal: Circulation Date: 2010-02-23 Impact factor: 29.690
Authors: C Zoccali; S Bode-Böger; F Mallamaci; F Benedetto; G Tripepi; L Malatino; A Cataliotti; I Bellanuova; I Fermo; J Frölich; R Böger Journal: Lancet Date: 2001 Dec 22-29 Impact factor: 79.321
Authors: Guy Eelen; Pauline de Zeeuw; Lucas Treps; Ulrike Harjes; Brian W Wong; Peter Carmeliet Journal: Physiol Rev Date: 2018-01-01 Impact factor: 37.312
Authors: Christoph Sinning; Arne Kieback; Philipp S Wild; Renate B Schnabel; Francisco Ojeda; Sebastian Appelbaum; Tanja Zeller; Edith Lubos; Edzard Schwedhelm; Karl J Lackner; Eike S Debus; Thomas Munzel; Stefan Blankenberg; Christine Espinola-Klein Journal: Clin Res Cardiol Date: 2014-02-02 Impact factor: 5.460
Authors: Uta Erdbrügger; Jan T Kielstein; Kerstin Westman; Jennie Z Ma; Wenjun Xin; Stephanie M Bode-Böger; Mȧrten Segelmark; Niels Rasmussen; Kirsten De Groot Journal: Eur J Rheumatol Date: 2018-04-02
Authors: Yiyi Zhang; Elena Blasco-Colmenares; Amy C Harms; Barry London; Indrani Halder; Madhurmeet Singh; Samuel C Dudley; Rebecca Gutmann; Eliseo Guallar; Thomas Hankemeier; Gordon F Tomaselli; Alan Cheng Journal: Europace Date: 2015-10-25 Impact factor: 5.214
Authors: Jeong Su Kim; Chang Hoon Kim; Kook Jin Chun; June Hong Kim; Yong Hyun Park; Jun Kim; Jin Hee Choi; Sang Hyun Lee; Eun Jung Kim; Dae Gon Yu; Eun Young Ahn; Myung Ho Jeong Journal: Clin Res Cardiol Date: 2013-08-28 Impact factor: 5.460
Authors: Insa E Emrich; Adam M Zawada; Jens Martens-Lobenhoffer; Danilo Fliser; Stefan Wagenpfeil; Gunnar H Heine; Stefanie M Bode-Böger Journal: Clin Res Cardiol Date: 2017-11-03 Impact factor: 5.460